Tralesinidase alfa

Summary

Tralesinidase alfa is an investigational enzyme replacement therapy designed for mucopolysaccharidosis type IIIB (Sanfilippo syndrome B), a rare pediatric lysosomal storage disorder. The drug is a recombinant fusion of human N‑acetyl‑α‑glucosaminidase (NAGLU) and a modified insulin‑like growth factor‑2 (IGF2) tag, intended to restore the missing lysosomal enzyme activity and reduce heparan‑sulfate buildup in the brain and other tissues.

Mechanism of Action

The NAGLU component of tralesinidase alfa provides the catalytic activity needed to cleave heparan‑sulfate within lysosomes. The IGF2 tag binds with high affinity to the cation‑independent mannose‑6‑phosphate/IGF2 receptor (CI‑MPR), enabling receptor‑mediated uptake of the fusion protein into neurons, astrocytes and other CNS cells. Once internalised, the enzyme reaches lysosomes, degrades accumulated heparan‑sulfate, and thereby mitigates the cellular pathology that drives neurodegeneration.

What the Research Shows

A phase I/II open‑label trial in 22 children with MPS IIIB administered tralesinidase alfa intracerebroventricularly (ICV). A 300 mg dose normalized heparan‑sulfate and its non‑reducing ends in cerebrospinal fluid and plasma, stabilized cortical gray‑matter volume, and reduced liver and spleen size over 48 weeks; cognitive age‑equivalent scores correlated with drug exposure. In a 20‑month canine study, weekly ICV infusions were well tolerated, achieved near‑normal heparan‑sulfate levels in CNS tissue, improved cognitive test performance, and lessened cerebellar atrophy. A juvenile cynomolgus monkey safety study showed that weekly ICV (or single IV) dosing produced widespread CNS distribution, predictable CSF pharmacokinetics, and minimal systemic effects; the only drug‑related findings were mild cellular infiltrates along the catheter tract and anti‑drug antibodies that did not markedly alter exposure. In vitro work demonstrated that the IGF2 tag drives CI‑MPR‑mediated uptake of the fusion protein into neurons and astrocytes at low nanomolar concentrations, whereas untagged NAGLU shows negligible uptake in these cells; microglia can acquire enzyme via a receptor‑independent route.

Reported Benefits

Available data indicate that tralesinidase alfa can normalize disease‑related heparan‑sulfate biomarkers in both central and peripheral compartments, which is a prerequisite for clinical benefit. Early human results suggest stabilization of brain volume and a possible link to improved cognitive trajectories. Animal studies show that long‑term treatment can prevent or markedly reduce biochemical accumulation, organomegaly, cerebellar atrophy, and cognitive decline, supporting its potential to modify disease progression.

Limitations of the Evidence

Human evidence is limited to an open‑label study with a modest sample size and a 48‑week observation period; no randomized control data are available. The optimal dose (300 mg) was identified only after dose escalation, and long‑term safety and efficacy remain unproven. Anti‑drug antibodies were detected, and their clinical relevance is unclear. Most efficacy signals are derived from animal models, which may not fully translate to patients. Regulatory status is investigational, and the therapy is not yet approved for clinical use.

Safety Considerations

Across preclinical and early clinical studies, tralesinidase alfa was generally well tolerated. In monkeys, the only drug‑related tissue findings were mild inflammatory cell infiltrates along the ICV catheter track, without functional impairment. No significant changes in vital signs, ECG, ophthalmology, or respiration were reported. Anti‑drug antibodies developed in some subjects but did not appear to affect drug exposure markedly. Human abstracts did not highlight serious adverse events, but safety data remain limited to the early trial duration.

How It Is Administered

Tralesinidase alfa is delivered directly into the ventricular system of the brain via intracerebroventricular (ICV) infusion, typically using a surgically implanted catheter. Both slow infusion and isovolumetric bolus techniques have been studied. The drug is a sterile recombinant protein formulation intended for infusion; other routes (e.g., intravenous) have been evaluated only in animal safety studies.

Routes of Administration

No administration routes recorded yet.

Goals & Uses

No goal associations recorded yet.

Contraindications

No contraindications recorded yet.

Adverse Effects

No adverse effects recorded yet.

Drug Interactions

No drug interactions recorded yet.

Population Constraints

No population constraints recorded yet.

Regulatory Status

No regulatory status recorded yet.

Evidence & Sources

• A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B
  Journal ArticleModerateMuschol N, et al.2023-01-01T00:00:00.000000Z
• Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB
  Journal ArticleLowEllinwood NM, et al.2022-01-01T00:00:00.000000Z
• Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys
  Journal ArticleLowPinkstaff J, et al.2023-01-01T00:00:00.000000Z
• BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis
  Journal ArticleLowYogalingam G, et al.2019-01-01T00:00:00.000000Z

Frequently Asked Questions